http://www.repligen.com./
For the complete story, click the link above and look under “what’s news”
Significant Treatment Effect
NEEDHAM, MA - July 20, 2001 - Repligen Corporation (Nasdaq:RGEN) today presented data from its Phase 2 clinical trial of secretin in autism at the annual meeting of the Autism Society of America in San Diego. The data showed that patients treated with secretin had an improvement in symptoms over the eight-week period of the trial using multiple types of assessments, which was particularly evident in a subgroup of patients defined by two biomarkers. The Company also presented a meta-analysis of four previously published Phase 1 studies involving smaller numbers of patients and fewer doses of secretin. In the four Phase 1 studies, clinical “responders” were defined with a Clinical Global Impression of improvement, the Preschool Language Scale, parental reports of improvement and the Childhood Autism Rating Scale respectively. In the meta analysis, responder data from the four studies was pooled to assess the rate of clinical response to secretin compared to a placebo. The outcome of this analysis showed a greater number of patients with a clinical response to secretin compared to placebo, a difference which was statistically significant (p=0.02).
Dad,
Thanks for the info…I can’t tell you how many of your posts I’ve fowarded to a friend who has a preschooler with autism. Needless to say this child, at the very least, is really benefitting from your experience and expertise.
Karyn